絞り込み

16645

広告

Impact of pretransplant donor-specific anti-HLA antibodies on cord blood transplantation on behalf of the Transplant Complications Working Group of Japan Society for Hematopoietic Cell Transplantation.

著者 Fuji S , Oshima K , Ohashi K , Sawa M , Saito T , Eto T , Tanaka M , Onizuka M , Nakamae H , Shiratori S , Ozawa Y , Hidaka M , Nagamura-Inoue T , Tanaka H , Fukuda T , Ichinohe T , Atsuta Y , Ogata M
Bone Marrow Transplant.2019 Oct 07 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (10view , 0users)

Full Text Sources

Graft failure (GF) remains a major complication of cord blood transplantation (CBT). Although the presence of pretransplant, donor-specific anti-HLA antibodies (DSA) was reported to be associated with an increased risk of GF after CBT, data are still limited. Thus, we conducted a retrospective analysis of recipients of single-unit CBT with pretransplant anti-HLA antibodies using the database of Japan Society for Hematopoietic Cell Transplantation (JSHCT). Data for recipients of single-unit CBT with pretransplant anti-HLA antibodies from 2010 to 2014 were obtained. In total, 343 patients who received CBT and who had detailed information about anti-HLA antibodies were included. The median age was 51 years (range, 0-71). Regarding DSA, 25 patients had a mean fluorescence intensity (MFI) ≥ 1000 (DSA-positive group) and 318 patients had a MFI <1000 (DSA-negative group). The cumulative incidence of neutrophil engraftment at 60 days after CBT was 75.7% (95% CI, 70.6-80.1) in the DSA-negative group and 56.0% (95% CI, 34.1-73.1) in the DSA-positive group (P = 0.03). In conclusion, pretransplant DSA with a MFI ≥ 1000 was associated with an increased risk of GF in single-unit CBT.
PMID: 31591450 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード